Cite
Ranki T, Pesonen S, Hemminki A, et al. Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer. 2016;4:17doi: 10.1186/s40425-016-0121-5.
Ranki, T., Pesonen, S., Hemminki, A., Partanen, K., Kairemo, K., Alanko, T., Lundin, J., Linder, N., Turkki, R., Ristimäki, A., Jäger, E., Karbach, J., Wahle, C., Kankainen, M., Backman, C., von Euler, M., Haavisto, E., Hakonen, T., Heiskanen, R., Jaderberg, M., Juhila, J., Priha, P., Suoranta, L., Vassilev, L., Vuolanto, A., & Joensuu, T. (2016). Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. Journal for immunotherapy of cancer, 417. https://doi.org/10.1186/s40425-016-0121-5
Ranki, Tuuli, et al. "Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers." Journal for immunotherapy of cancer vol. 4 (2016): 17. doi: https://doi.org/10.1186/s40425-016-0121-5
Ranki T, Pesonen S, Hemminki A, Partanen K, Kairemo K, Alanko T, Lundin J, Linder N, Turkki R, Ristimäki A, Jäger E, Karbach J, Wahle C, Kankainen M, Backman C, von Euler M, Haavisto E, Hakonen T, Heiskanen R, Jaderberg M, Juhila J, Priha P, Suoranta L, Vassilev L, Vuolanto A, Joensuu T. Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer. 2016 Mar 15;4:17. doi: 10.1186/s40425-016-0121-5. eCollection 2016. PMID: 26981247; PMCID: PMC4791966.
Copy
Download .nbib